This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Will Keytruda & Gardasil Aid Merck (MRK) Sales in Q4 Earnings?
by Zacks Equity Research
Merck's (MRK) key products like cancer drug Keytruda and HPV vaccine Gardasil are expected to have driven sales in Q4.
The Zacks Analyst Blog Highlights Expedia, IDEXX Laboratories, Tradeweb Markets, SolarEdge Technologies and Sanofi
by Zacks Equity Research
Expedia, IDEXX Laboratories, Tradeweb Markets, SolarEdge Technologies and Sanofi are included in this Analyst Blog.
J&J (JNJ) Down as Court Rejects Bankruptcy Claim in Talc Lawsuits
by Zacks Equity Research
A federal appeals court rejects J&J's (JNJ) efforts to shift over 38,000 lawsuits related to its talcum-based baby powder out of trial courts and into bankruptcy court.
Moderna (MRNA) RSV Jab For Older Adults Gets FDA Breakthrough Tag
by Zacks Equity Research
Moderna (MRNA) announces that the FDA granted Breakthrough Therapy Designation to its respiratory syncytial virus (RSV) vaccine candidate, mRNA-1345 for the prevention of respiratory disease in older adults.
Can Sanofi (SNY) Keep the Beat Streak Alive in Q4 Earnings?
by Zacks Equity Research
Sanofi's (SNY) top line is likely to have been driven by higher sales of Dupixent and vaccines.
Top 5 Nasdaq Composite Stocks to Buy Ahead of Q4 Earnings
by Nalak Das
Five Nasdaq Composite companies are set to beat earnings estimates. These are: EXPE, IDXX, SNY, TW and SEDG.
2 Medical Stocks to Consider Buying Before Earnings
by Shaun Pruitt
There is a continued need for prosperous healthcare companies, here are two medical stocks investors may want to consider buying ahead of earnings this week.
Will Eylea and Dupixent Fuel Regeneron's (REGN) Q4 Earnings?
by Zacks Equity Research
Regeneron's (REGN) fourth-quarter earnings are likely to have gotten a boost from the solid performances of Eylea and Dupixent.
Eli Lilly (LLY) Lymphoma Candidate Pirtobrutinib Gets FDA Nod
by Zacks Equity Research
The FDA approves Eli Lilly's Jaypirca (pirtobrutinib) under an accelerated approval pathway as a treatment for mantle cell lymphoma (MCL).
Merck (MRK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda when the company reports Q4 earnings.
Sanofi (SNY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Sanofi (SNY) closed at $48.49, marking a -0.66% move from the previous day.
Bristol-Myers (BMY) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Investors are likely to focus on the demand for Eliquis and Opdivo, along with an incremental contribution from newer drugs, when Bristol-Myers (BMY) reports Q4 results.
Weibo and Viasat have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Weibo and Viasat are part of the Zacks Bull and Bear of the Day article.
Eli Lilly (LLY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) fourth-quarter sales.
Is a Beat on the Cards for Novo Nordisk (NVO) in Q4 Earnings?
by Zacks Equity Research
Novo Nordisk's (NVO) top line is likely to have been driven by sales of its Diabetes and Obesity Care products in the fourth quarter of 2022.
Zacks.com featured highlights include Navios Maritime Partners, Hewlett Packard Enterprise, Aegon, Cowen and Sanofi
by Zacks Equity Research
Navios Maritime Partners, Hewlett Packard Enterprise, Aegon, Cowen and Sanofi are part of the Zacks Screen of the Week article.
Can Pfizer (PFE) Beat Expectations This Earnings Season?
by Zacks Equity Research
Higher alliance revenues from Eliquis, higher sales of Prevnar vaccines and drugs like Vyndaqel/Vyndamax are likely to have contributed to Pfizer's (PFE) sales growth in Q4.
Elevance Health (ELV) Tops on Q4 Earnings, Hikes Dividend
by Zacks Equity Research
Elevance Health's (ELV) fourth-quarter earnings gain on solid premiums from its Medicaid business. Management approves a quarterly dividend hike of 16%.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
5 Value Stocks With Exciting EV-to-EBITDA Ratios to Own Now
by Anindya Barman
We have screened value stocks NMM, HPE, AEG, COWN and SNY based on the EV-to-EBITDA ratio, which offers a clearer picture of valuation and earnings potential.
Gilead (GILD) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its fourth-quarter 2022 results.
Novartis' (NVS) Unit to Acquire Astellas' Rights of Mycamine
by Zacks Equity Research
Novartis' (NVS) generic unit Sandoz is set to acquire rights to the antifungal product Mycamine from Astellas.
J&J (JNJ) Q4 Earnings Beat, Sales Miss, 2023 EPS View Upbeat
by Zacks Equity Research
J&J (JNJ) beats estimates for fourth-quarter earnings but misses the same for sales. Its EPS outlook for 2023 is above expectations while sales fall short.
Sanofi (SNY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Sanofi (SNY) closed at $48.63, marking a -0.92% move from the previous day.
Lilly (LLY) Jardiance Kidney Disease sNDA Gets FDA Acceptance
by Zacks Equity Research
Eli Lilly's (LLY) sNDA seeks approval for diabetes medicine, Jardiance, to reduce the risk of kidney disease progression and cardiovascular death in adults with CKD.